Page last updated: 2024-10-27

glimepiride and Atherosclerosis

glimepiride has been researched along with Atherosclerosis in 12 studies

glimepiride: structure given in first source

Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.

Research Excerpts

ExcerptRelevanceReference
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)."9.34Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020)
"To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes."9.13Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008)
"Glimepiride appears to improve insulin resistance and atherosclerotic disorders."9.12Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006)
"The purpose of this study was to examine the potential prophylactic effect of glimepiride on experimental atherosclerosis in rabbits and to elucidate the mechanism of action."7.73Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. ( Oshima, K; Shakuto, S; Tsuchiya, E, 2005)
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)."5.34Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020)
"To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes."5.13Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008)
"Glimepiride appears to improve insulin resistance and atherosclerotic disorders."5.12Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006)
"The purpose of this study was to examine the potential prophylactic effect of glimepiride on experimental atherosclerosis in rabbits and to elucidate the mechanism of action."3.73Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. ( Oshima, K; Shakuto, S; Tsuchiya, E, 2005)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (83.33)29.6817
2010's1 (8.33)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Werida, R1
Kabel, M1
Omran, G1
Shokry, A1
Mostafa, T1
Shah, R1
Fresco, C1
Tawakol, A1
Finn, AV1
Yang, B1
Tian, H1
Ren, Y1
Tong, N1
Yu, H1
Han, L1
Ran, X1
Forst, T1
Hohberg, C1
Fuellert, SD1
Lübben, G1
Konrad, T1
Löbig, M1
Weber, MM1
Sachara, C1
Gottschall, V1
Pfützner, A1
Shakuto, S1
Oshima, K1
Tsuchiya, E1
Koshiba, K1
Nomura, M1
Nakaya, Y1
Ito, S1
Giugliano, D1
Esposito, K1
Kida, Y1
Sato, T1
Steg, PG1
Marre, M1
Nissen, SE1
Nicholls, SJ1
Wolski, K1
Nesto, R1
Kupfer, S1
Perez, A1
Jure, H1
De Larochellière, R1
Staniloae, CS1
Mavromatis, K1
Saw, J1
Hu, B1
Lincoff, AM1
Tuzcu, EM1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560]Phase 480 participants (Actual)Interventional2018-10-08Completed
A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr[NCT00225277]Phase 3547 participants (Actual)Interventional2003-07-31Completed
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445]Phase 477 participants (Actual)Interventional2008-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

InterventionParticipants (Number)
Pioglitazone QD5
Glimepiride QD6

Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

InterventionParticipants (Number)
Pioglitazone QD40
Glimepiride QD41

Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

Interventionparticipants (Number)
Pioglitazone QD11
Glimepiride QD13

Nominal Change From Baseline in Normalized Total Atheroma Volume

The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)

,
InterventionPercent volume (Least Squares Mean)
BaselineNominal Change from Baseline
Glimepiride QD217.619-1.480
Pioglitazone QD206.579-5.528

Nominal Change From Baseline in Percent Atheroma Volume

The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)

,
InterventionPercent volume (Least Squares Mean)
BaselineNominal Change from Baseline
Glimepiride QD40.0160.725
Pioglitazone QD40.592-0.161

Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee

The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks

,
InterventionNumber of Events (Number)
Nonfatal Myocardial InfarctionNonfatal StrokeCoronary Revascularization: PCI/CABG counted onceCoronary Revascularization: PCICoronary Revascularization: CABGCarotid Endarterectomy/StentingHospitalization for Unstable AnginaCHF Hospitalization: new/exacerbated counted onceHospitalization for New CHFHospitalization for Exacerbated CHFNoncardiovascular MortalityCardiovascular MortalityComposite Endpoint AComposite Endpoint BComposite Endpoint C
Glimepiride QD4130282025231164113
Pioglitazone QD2029255144400354011

Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmmol/l (Mean)
Baseline FSG3rd Month FSG
Metformin ( 002 Group)6.26.5
Pioglitazone (001 Group)6.95.4

Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionμU/ml (Mean)
Baseline FSI3rd month FSI
Metformin ( 002 Group)13.013.9
Pioglitazone (001 Group)16.212.3

Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HbA1c3rd month HbA1c
Metformin ( 002 Group)7.87.0
Pioglitazone (001 Group)7.36.7

Comparison of Changes in HOMA Percent B and HOMA Percent S With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HOMA percent beta cells function3rd month HOMA percent beta cells functionBaseline HOMA percent sensitivity3rd month HOMA percent sensitivity
Metformin ( 002 Group)109.3116.076.267.2
Pioglitazone (001 Group)118.9132.351.169.3

Comparison of Changes in Insulin Levels (HOMA IR,QUICKI) With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionScore on a scale ( SI unit) (Mean)
Baseline QUICKI3rd month QUICKIBaseline HOMA IR3rd month HOMA IR
Metformin ( 002 Group)0.570.543.74.3
Pioglitazone (001 Group)0.520.595.12.9

Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmg/dl (Mean)
Baseline TC3rd month TCBaseline TG3rd month TGBaseline HDL3rd month HDLBaseline LDL3rd month LDL
Metformin (002 Group)193.0177.0166.0175.034.434.7125.6112.0
Pioglitazone (001 Group)182.01781831953333.2112.8105.5

Trials

4 trials available for glimepiride and Atherosclerosis

ArticleYear
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
    Diabetes research and clinical practice, 2020, Volume: 170

    Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus,

2020
Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2005, Volume: 37, Issue:8

    Topics: Aged; Atherosclerosis; Biomarkers; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypo

2005
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.
    The journal of medical investigation : JMI, 2006, Volume: 53, Issue:1-2

    Topics: Adipocytes; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Female; Glyburide; Humans;

2006
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008

Other Studies

8 other studies available for glimepiride and Atherosclerosis

ArticleYear
Pioglitazone vs glimepiride in the PERISCOPE trial.
    JAMA, 2008, Aug-20, Volume: 300, Issue:7

    Topics: Atherosclerosis; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; H

2008
Pioglitazone vs glimepiride in the PERISCOPE trial.
    JAMA, 2008, Aug-20, Volume: 300, Issue:7

    Topics: Atherosclerosis; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-C

2008
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art

2011
[The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2005, Volume: 22, Issue:3

    Topics: Acarbose; Atherosclerosis; Body Mass Index; Case-Control Studies; Cholesterol, HDL; Diabetes Mellitu

2005
Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits.
    Atherosclerosis, 2005, Volume: 182, Issue:2

    Topics: Animals; Aorta; Atherosclerosis; Cells, Cultured; Cholesterol, Dietary; Copper; Coronary Vessels; En

2005
Pioglitazone vs glimepiride and carotid intima-media thickness.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglyce

2007
Pioglitazone vs glimepiride and carotid intima-media thickness.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Huma

2007
Does PERISCOPE provide a new perspective on diabetic treatment?
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea

2008